PHYSIOTHERAPY BASED APPROACHES TO PATIENT REHABILITATION AND DENTAL EXPERTISE FOR JAW AND FACIAL PAIN
With
Darron Goralsky,
CEO & Clinical Director
Melbourne TMJ & Facial Pain Centre
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Melbourne | November 2025
Darron Goralsky is the Founder, CEO and Clinical Director of Melbourne TMJ & Facial Pain Centre, one of Australia’s leading multidisciplinary clinics dedicated to the assessment and management of temporomandibular disorders (TMD) and craniofacial pain.
With over 30 years of experience treating TMJ, facial and neck-related conditions, Darron originally trained as a Physiotherapist in South Africa, completing post graduate certifications in Manipulative Therapy. After his arrival in Melbourne he then continued with studies in Craniosacral Therapy. Early in his career, Darron identified a major gap in how jaw and facial pain conditions were managed—recognising the need for a collaborative approach that integrates manual therapy and other physiotherapy based approaches to patient rehabilitation, and dental expertise.
This insight led to the development of the Goralsky Craniomandibular Method (GCMM), a structured multidisciplinary protocol combining physiotherapy principles with dental and medical collaboration. Darron has lectured to many dental and allied health groups, was part of a 4 person lecture team for a one day course on TMD for the University of Melbourne’s Dental School, and presented at the 2019 ANZAOP Conference. In 2024, Darron was an invited speaker at the Myofocus Functional Health Symposium in Melbourne, presenting on multidisciplinary management of TMD and orofacial pain. Darron has also presented a 5-hour Masterclass for dentists as part of Dr Damian Teo’s Mini Residency in TMD & Sleep for the last 5 years. Building on this momentum, he developed and successfully delivered his inaugural 2-day intensive professional education program for dental professionals, The 5-Step TMD Protocol Course, in October 2025.
A passionate educator and mentor, Darron now focuses on training and developing clinicians in his evidence-based approach. His growing team includes TMJ physiotherapists, osteopaths, dentists, and orofacial myofunctional therapists, a breathing educator and a GP working collaboratively to deliver comprehensive patient care. Darron is an active member of the Australian Physiotherapy Association (APA), the American Academy of Craniofacial Pain (AACP), and the Australia and New Zealand Academy of Orofacial Pain (ANZAOP).
Source: Supplied and adapted
-
New reimagined identity LifeSciences Australia repositions for sector
In June 2026, ARCS Australia formally became LifeSciences Australia — a name chosen to reflect the role the organisation plays across Australia’s life sciences sector.
Over more than 40 years, ARCS has grown well beyond its origins as a training and education body for regulatory and clinical specialists. Today, the organisation supports professionals across the entire life sciences sector — from early research through regulation, development and commercialisation — through an expanding range of programs and initiatives.
-
Research funded to investigate early-onset bowel cancer progression
Bowel Cancer Australia recently announced a team led by Professor Michael Samuel as the successful applicant for a three-year $600k early-onset bowel cancer research project through the 2023 round of Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS).
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
